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Background: The protein neutrophil gelatinase-associated lipocalin (NGAL) is a mediator synthesized and released
by neutrophils. Its physiological function is as yet unclear. Levels in blood increase in several inflammatory diseases.
High serum values indicate poor prognosis for several diseases. Pleural effusion may appear as the result of various
pathologies. The most common cause is heart failure (HF). Other common causes include parapneumonic (PPE) and
malignant (MPE) pleural effusions, and pulmonary embolism. Tubercular effusion (TE) is commonly encountered in
Turkey and similar developing countries. The purpose of this study was to investigate the effectiveness of NGAL, a
current inflammation marker, in discriminating between different etiological diseases that cause pleural effusion.
Methods: The study was performed at the Recep Tayyip Erdoğan University Faculty of Medicine Chest Diseases
Clinic. One hundred patients were included in the study, 25 with parapneumonic effusion, 25 with heart
failure-related effusion, 25 with tubercular effusion and 25 with cancer-related effusion. NGAL was measured in
patients’ serum and pleural fluids.
Results: Serum NGAL levels in PPE (171 ± 56 ng/ml) were significantly higher (p < 0.001) than those in HF (86 ±
31 ng/ml), CA (103 ± 42 ng/ml) and TE (63 ± 19 ng/ml). Pleural NGAL levels were also significantly higher in PPE
compared to HF, MPE and TE (p < 0.001). Serum NGAL levels exhibited a positive correlation with white blood cell
(WBC), neutrophil, C-reactive protein (CRP), sedimentation, serum LDH, creatinine, pleural leukocyte and pleural
neutrophil numbers. The most significant correlation was between NGAL level and WBC (p < 0.001, r = 0.579). Both
serum and pleural NGAL levels are highly effective in differentiating patients with PPE from those without PPE
(AUC: 0.910 and 0.790, respectively).
Conclusions: NGAL can be used in the diagnosis of diseases with an acute inflammatory course. Serum and pleural
NGAL levels can differentiate PPE from other diseases causing pleural fluid with high sensitivity and specificity.
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Neutrophil gelatinase-associated lipocalin (NGAL), also
known as lipocalin-2, is a 25 kDa protein [1] synthesized,
stored and released under different clinical conditions in
neutrophil granules [2]. It is released in the lung, colon,
pancreas, breast and several healthy tissues. The func-
tion of this substance is still unclear, although it is
thought to play a role in the body’s immune response.* Correspondence: ozkayasevket@yahoo.com
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unless otherwise stated.An increase in serum or plasma NGAL levels has been
shown in acute and chronic inflammatory diseases, is-
chemic diseases such as stroke and myocardial infarc-
tion, metabolic diseases such as obesity and type 2
diabetes mellitus, acute or chronic kidney failure, follow-
ing heart and kidney transplantation and in solid tumors
such as lung, colon and breast cancer [3-5]. It is thought
to be involved in the emergence and progression of sev-
eral diseases [6]. In clinical practice it is used as a bio-
marker showing early acute renal injury [7].
Pleural effusion may appear as the result of various
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(PPE) and malignant (MPE) pleural effusions, and pul-
monary embolism. Tubercular effusion (TE) is com-
monly encountered in Turkey and similar developing
countries. Diagnosis of the disease causing pleural effu-
sion is possible after systematic evaluation and various
interventional procedures. In pleural effusion of un-
known origin, transudate and exudate must first be dif-
ferentiated using thoracentesis. Light’s criteria described
in 1972 are still used for this purpose [8]. Biomarkers
capable of establishing etiological diagnosis without inva-
sive procedures have been investigated in exudate fluids.
An adenosine deaminase (ADA) level above 70 U/ml is
regarded as adequate for diagnosing pleural tuberculosis
and has eliminated the need for invasive techniques such
as pleural biopsy [9].
Our scan of the literature revealed no studies involving
NGAL measurement in serum and pleural fluid in the
diagnosis of diseases leading to pleural effusion. The
purpose of this study was to investigate the efficacy of
the inflammation marker NGAL in differentiating vari-
ous etiological diseases leading to pleural effusion.
Methods
Patients
The study was performed at the RecepTayyipErdoğan
University Faculty of Medicine Chest Diseases Clinic,
Turkey. Local ethical committee approval was obtained
before the study commenced, and signed consent forms
were received from patients. Patients presenting to the
clinic or admitted to the department with pleural effu-
sion between March, 2013, and May, 2014, were in-
cluded. Total protein, albumin and lactic dehydrogenase
(LDH) measurements were performed in serum and
pleural fluid, and transudate/exudate differentiation was
made on the basis of light criteria. One hundred patients
aged over 18 and diagnosed with HF, PPE, TE or CA-
related pleural effusion following advanced tests were
enrolled. NGAL, total protein, albumin, LDH, total chol-
esterol and hemogram measurements were performed
for all participants. Creatinine, CRP and sedimentation
were investigated in blood only.
Exclusion criteria
Subjects with chronic renal failure, receiving diuretic ther-
apy due to heart failure or using antibiotics were excluded.
Pleural and serum NGAL measurement
10 ml venous blood and 10 ml pleural fluid specimens
were collected and centrifuged within 1 h (at 3000 g/min
for 10 min). That part of the pleural fluid that was not pre-
cipitated and the blood serum were placed into Eppendorf
tubes by pipette. Specimens were stored in a deep freeze
at -80 degrees. NGAL measurements were performedwhen a sufficient number had been obtained. Measure-
ments were performed quantitatively using the enzyme-
linked immune absorbent assay (ELISA) method with
Biovendor Research and Diagnostic Products (Heidelberg,
Germany) NGAL antibodies.
Statistical analysis
Statistical analyses were performed using SPSS (SPSS
version 16; SPSS Inc., Chicago, IL, USA) software. Con-
stant variables were expressed as mean ± SD and cat-
egorical variables as %. Student’s t test was used in the
comparison of parametric variables and the Mann-
Whitney U test in the comparison of non-parametric
variables between two groups. For comparisons among
more than two groups, ANOVA was used for parametric
variables and the Kruskal-Wallis test for non-parametric
variables. Correlations between variables were investi-
gated using Spearman’s correlation analysis. The χ
square test was used to compare categoric variables.
ROC curve analysis was used to determine the specifi-
city, sensitivity and cut-off value of NGAL in serum and
pleural fluid to distinguish between transude and exud-
ate. Significance was set at p < 0.05.
Results
One hundred patients, 25 with heart failure-related
pleural effusion (25%), 25 with cancer-related pleural ef-
fusion (25%), 25 with parapneumonic pleural effusion
(25%) and 25 with tubercular pleural effusion (25%) were
included in the study. Out of the 25 cancer cases, 21
were lung cancers (17 non-small cell lung cancer, 4 small
cell lung cancer), 3 breast cancers and 1 non-Hodgkin’s
lymphoma. Mean age of the patients in the TE group
was significantly lower than that in the other groups
(p < 0.001). There was no difference among groups in
terms of gender. The inflammation markers serum
leukocyte, sedimentation rate and CRP levels were sig-
nificantly higher in the PPE group compared to the
other groups (p < 0.001). A comparison of patients di-
vided into etiological groups is shown in Table 1. Serum
NGAL levels were significantly higher in the PPE group
compared to the HF, MPE and TE groups. Mean NGAL
values in these groups were 171 ± 56 ng/ml, 86 ± 31 ng/ml,
103 ± 42 ng/ml and 63 ± 19 ng/ml, respectively (p < 0.001).
Serum NGAL levels in the MPE group were also higher
than those in the TE group (p = 0.013). There were no
other significant differences among the groups. Similarly,
pleural effusion NGAL levels in the PPE group were sig-
nificantly higher than those in the HF, MPE and TE
groups. Mean NGAL values in these groups were 147 ±
71 ng/ml, 84 ± 23 ng/ml, 74 ± 22 ng/ml and 75 ± 43 ng/ml,
respectively (p < 0.001). No differences in terms of pleural
effusion NGAL levels were observed among the HF, MPE
and TE groups.
Table 1 Comparison of groups by etiology
Causes of effusion (N) HF (25) MPE (25) PPE (25) TE (25) p
Age* 75 ± 9 71 ± 12 69 ± 16 39 ± 12 <0.001
Sex (W/M) 4/21 7/18 5/50 11/14 0.154
NGAL(S) (ng/ml)** 86 ± 31 103 ± 42 171 ± 56 63 ± 19 <0.001
NGAL(Pl) (ng/ml)** 84 ± 23 74 ± 22 147 ± 71 75 ± 43 <0.001
NGAL rate (Pl/S)* 1,05 ± 0,35 0,86 ± 0,43 0,99 ± 0,72 1,27 ± 0,71 0.158
Sedimentation rate (mm/hour)* 32 ± 20 57 ± 18 72 ± 24 49 ± 11 <0.001
CRP (mg/dl)** 2,2 ± 1,7 5,6 ± 3,1 17,3 ± 7,9 10,6 ± 5,2 <0.001
WBC (/ml)** 6615 ± 1490 9967 ± 4234 13826 ± 4723 6911 ± 1101 <0.001
Neutrophils (/ml)** 5005 ± 2164 7202 ± 4854 11326 ± 5430 4802 ± 1273 <0.001
Pl. Leukocytes (/ml)** 571 ± 382 868 ± 1262 2841 ± 4302 3072 ± 1625 0.001
Pl. Neutrophils (/ml)** 149 ± 213 257 ± 466 2530 ± 3553 744 ± 406 <0.001
* = Variables with parametric distribution. ** = Variables with non-parametric distribution.
CRP, C-Reactive protein; HF, Heart failure; N, Number of patients; ng/ml, nanogram/milliliter; M, Men; MPE, Malignant pleural effusion; Pl, Pleural effusion; PPE,
Parapneumonic pleural effusion; S, Serum; TE, Tubercular effusion; W, Women; WBC, White blood count.
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to determine relations between serum and pleural NGAL
levels and age and other constant variables. Serum NGAL
levels were positively correlated with blood WBC, blood
neutrophil numbers, CRP, sedimentation rate, serum
LDH, creatinine, pleural WBC and pleural neutrophil
numbers. Pleural NGAL was positively correlated with
CRP, blood WBC, blood neutrophil numbers and serum
LDH. However, there was no correlation between pleural
NGAL and pleural WBC or pleural neutrophils (Table 2).
The most significant correlation was between serum
NGAL level and blood WBC (p < 0.001, r = 0.579). This
correlation is shown in Figure 1. A significant positive cor-
relation was found between serum NGAL and blood neu-
trophil number (p < 0.001, r = 0.504). Pleural NGAL rose
in line with serum NGAL (p = 0.001, r = 0.366) (Figure 2).Table 2 Correlation between serum and pleural fluid
NGAL levels and constant variables








Age 0.109 0.337 0.093 0.410
CRP 0.473 <0.001 0.293 0.008
WBC 0.579 <0.001 0.445 <0.001
Neutrophils 0.504 <0.001 0.433 0.001
Sedimentation rate 0.347 0.002 0.107 0.347
LDH 0.457 <0.001 0.278 0.038
Creatinine 0.220 0.050 0.080 0.480
Pleural leukocytes 0.286 0.036 0.075 0.589
Pleural neutrophils 0.471 0.003 0.089 0.596
Pleural NGAL 0.366 0.001Since both serum and pleural NGAL levels were sig-
nificantly elevated in the PPE group, the HF, MPE and
TE group patients were combined into one non-PPE
group. This group consisting of 75 non-PPE individuals
was compared with the 25 PPE patients. Serum NGAL
level in the non-PPE group was 84 ± 35 ng/ml, compared
to 171 ± 51 ng/ml in the PPE group (p < 0.001). Similarly,
pleural NGAL levels in the PPE group (148 ± 65 ng/ml)
were significantly higher (p < 0.001) than in the non-PEE
group (78 ± 30 ng/ml). The variation between the groups
is shown in Figures 3 and 4. ROC curve analysis was
performed to determine the efficacy of serum and
pleural NGAL levels in discriminating between PPE and
non-PPE patients. Both serum and pleural NGAL levels
had high efficacy in discriminating between PPE and
non-PPE patients. AUC for serum NGAL was 0.910, and
AUC for pleural NGAL was 0.790. This characteristic of
serum and pleural NGAL is shown in Figure 5. PPE pa-
tients could be differentiated from non-PPE patients
with 89% specificity and 80% sensitivity at a cut-off value
124 ng/ml for serum NGAL, and with 89% specificity
and 75% specificity at a cut-off value of 104 ng/ml for
pleural NGAL. At a cut-off value of 188 ng/ml serum
NGAL diagnosed PPE with 100% specificity. Pleural
NGAL values of 210 ng/ml and above can differentiate
PPE from other diseases with 100% specificity.
Discussion
Pleural effusion is one of the main causes of admissions
to chest disease clinics. Clinical problems of pleural fluid
origin represent approximately 4% of all applications to
internal diseases clinics [10]. The first procedure to be
performed when pleural fluid of unknown causes is en-
countered is thoracentesis and transudate/exudate differ-
entiation. The exudate requires advanced examination.
Figure 1 Positive correlation between serum NGAL level and WBC.
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sis of the primary disease without requiring invasive pro-
cedures. However, only pleural adenosine deaminase
(ADA) measurement has entered into routine practice.
ADA values above 70 U/ml are regarded as sufficient for
diagnosis of pleural tuberculosis. ADA above 40 U/ml is
regarded as sufficient for diagnosis in patients aged under
35 in regions in which tuberculosis is widespread [11].Figure 2 Positive correlation between serum and pleural NGAL.In this study we investigated the ability of NGAL to
identify specific diseases responsible for pleural effusion.
We showed that both serum and pleural NGAL levels
differentiated PPE from other causes of PPE, such as HF,
MPE and tuberculosis. Serum NGAL levels established
this differentiation more efficiently than pleural NGAL
levels. Serum NGAL levels above 188 ng/ml and pleural
NGAL levels above 210 ng/ml can distinguish PPE with
Figure 3 Boxplot chart of serum NGAL levels of the PPE and non-PPE groups.
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that it is the first one measuring NGAL in pleural fluid.
Several previous studies have measured NGAL in blood
serum or plasma and less frequently in urine. Most stud-
ies concerning NGAL have been concerned with it as an
early marker of acute renal injury [12,13]. NGAL is spe-
cifically released in response to nephron damage in
acute renal injury, and its rise in blood and urine is a
poor prognostic factor [14,15]. NGAL measurementsFigure 4 Boxplot chart of pleural NGAL levels of the PPE and non-PPEdirected toward acute renal injury have gradually begun
appearing in routine clinical practice. NGAL has rarely
been investigated in body fluids other than blood and
urine. NGAL measurement has been performed in
phlegm in chronic obstructive pulmonary disease [16,17]
and in bronchoalveolar lavage [18]. In our study, serum
and pleural NGAL were high in PPE and pneumonia,
that is an acute infection. Previous studies have shown
that NGAL rises in acute infections. Axelsson et al.groups.
Figure 5 ROC curve showing effectiveness of serum and Pleural NGAL in differentiating PPE.
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were 10 times higher than those of a healthy control
group [19]. Chakraborty et al. reported that serum
NGAL levels were correlated with the severity of the dis-
ease in patients with acute pancreatitis [4]. One recent
study involving children with pneumonia in Africa
showed that serum NGAL levels were highly specific
and sensitive in differentiating severe pneumonia and
bacterial pneumonia [20]. That same study reported that
at a cut-off value of ≥ 130.1 ng/ml for NGAL was able to
predict bacterial pneumonia with 85.7% specificity and
83.7% sensitivity. Another recent study reported that
plasma NGAL levels increased significantly in patients
with disseminated intravascular coagulation [21]. In our
study, serum NGAL levels were increased in acute infec-
tions, and both serum and pleural NGAL levels in pa-
tients with PPE (an acute, infectious complication of
pneumonia) were significantly higher than those in pa-
tients with heart failure, cancer and tuberculosis. At a
cut-off value of 124 ng/ml, NGAL was able to differenti-
ate PPE from the other diseases at the high levels of 89%
specificity and 80% sensitivity. A cut-off value of 104 ng/
ml for pleural NGAL predicted patients with PPE with
89% specificity and 75% sensitivity. PPE can be diag-
nosed in patients with difficult to diagnose pleural effu-
sion if serum NGAL level is ≥ 188 and/or pleural NGAL
level is ≥ 210. Of course, these data need to be confirmed
in wider series studies.
Another important finding in this study is the positive
correlation between serum NGAL level and the acuteinflammation markers WBC, neutrophils and CRP. In a
study of patients with HIV, Landro et al. reported a posi-
tive correlation between serum NGAL and neutrophil
numbers [22]. Similarly, Allegra et al. showed a positive
correlation between serum NGAL levels and leukocyte
(WBC) and neutrophil numbers [23]. Our results are
in close agreement with those of these studies. Serum
NGAL levels rise significantly in acute inflammation,
and increase together with those of other inflammation
markers. NGAL would seem to be a biomarker that can
be used in the diagnosis or monitoring of acute infec-
tion. We think that wider-ranging studies are needed
to elucidate this property of NGAL. Eagan et al. [24] de-
termined a positive correlation between serum NGAL
levels and neutrophil, CRP and creatinine levels in
patients with chronic obstructive pulmonary disease
(COPD). NGAL rises in correlation with other inflam-
mation markers, not only in acute but also in chronic in-
flammation. A novel biomarker has been reported in
order to discriminate parapneumonic from other exuda-
tive effusions. High concentrations of Pentraxin-3(PTX-
3) in pleural effusions are very sensitive to differentiate
PPE from non-PPE, while they do not seem able to dif-
ferentiate between uncomplicated and complicated
pleural effusions [25].
Last but not least, this study has revealed that pleural/
serum NGAL levels were similar in all four disease
groups. NGAL levels do not seem practicable in the dif-
ferentiation between transudate and exudate and specific
diseases.
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In conclusion, we can say this is the first study in which
NGAL has been investigated in terms of diagnosis in
diseases progressing with pleural effusion. Both serum
NGAL and pleural NGAL measurements can differenti-
ate PPE from pleural effusion associated with heart fail-
ure, cancer and tuberculosis. In addition, NGAL can be
used in the diagnosis of PPE and pneumonia.
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